Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 171,300 Shares of Gilead Sciences, Inc. $GILD

Fjarde AP Fonden Fourth Swedish National Pension Fund grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 58.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 466,363 shares of the biopharmaceutical company’s stock after buying an additional 171,300 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Gilead Sciences were worth $64,997,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in GILD. Paulson Wealth Management Inc. lifted its holdings in Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares during the last quarter. Essex Financial Services Inc. increased its holdings in shares of Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares during the last quarter. Davidson Trust Co. raised its position in shares of Gilead Sciences by 4.1% in the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 74 shares during the period. Alpha Cubed Investments LLC lifted its stake in shares of Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 75 shares during the last quarter. Finally, Personal CFO Solutions LLC boosted its holdings in shares of Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 76 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 4.2%

Shares of Gilead Sciences stock opened at $131.27 on Friday. The firm has a market capitalization of $162.98 billion, a PE ratio of 17.88 and a beta of 0.32. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The firm’s 50 day moving average is $129.48 and its 200 day moving average is $134.56. Gilead Sciences, Inc. has a 1 year low of $107.75 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the firm earned $1.81 EPS. The firm’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were issued a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00. Following the completion of the transaction, the chief executive officer owned 607,133 shares of the company’s stock, valued at $76,674,826.57. This represents a 2.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 83,000 shares of company stock worth $10,824,500 in the last 90 days. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Morgan Stanley lowered their target price on Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. The Goldman Sachs Group upped their target price on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, April 17th. Weiss Ratings lowered Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Rothschild & Co Redburn decreased their price target on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Finally, Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research note on Wednesday, May 20th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $158.41.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.